Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
dupilumab interleukin 4 receptor alpha NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Maintenance[MeSHID:D008283]
Bronchial Spasm[MeSHID:D001986]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Status Asthmaticus[MeSHID:D013224]
Dermatitis
Atopic[MeSHID:D003876]
Nasal Polyps[MeSHID:D009298]
eosinophil[MeSHID:D004804]
Phenotype[MeSHID:D010641]
Prescription procedure[MeSHID:D055656]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 50.92 approved antagonist
dupilumab interleukin-4 receptor subunit alpha biotech NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Maintenance[MeSHID:D008283]
Bronchial Spasm[MeSHID:D001986]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Status Asthmaticus[MeSHID:D013224]
Dermatitis
Atopic[MeSHID:D003876]
Nasal Polyps[MeSHID:D009298]
eosinophil[MeSHID:D004804]
Phenotype[MeSHID:D010641]
Prescription procedure[MeSHID:D055656]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 50.92 approved,investigational antagonist
dupilumab interleukin 4 receptor alpha NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Maintenance[MeSHID:D008283]
Bronchial Spasm[MeSHID:D001986]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Status Asthmaticus[MeSHID:D013224]
Dermatitis
Atopic[MeSHID:D003876]
Nasal Polyps[MeSHID:D009298]
eosinophil[MeSHID:D004804]
Phenotype[MeSHID:D010641]
Prescription procedure[MeSHID:D055656]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 50.92 approved antibody
dupilumab interleukin-4 receptor subunit alpha biotech NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Maintenance[MeSHID:D008283]
Bronchial Spasm[MeSHID:D001986]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Status Asthmaticus[MeSHID:D013224]
Dermatitis
Atopic[MeSHID:D003876]
Nasal Polyps[MeSHID:D009298]
eosinophil[MeSHID:D004804]
Phenotype[MeSHID:D010641]
Prescription procedure[MeSHID:D055656]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 50.92 approved,investigational antagonist,antibody
dupilumab interleukin 4 receptor alpha NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Maintenance[MeSHID:D008283]
Bronchial Spasm[MeSHID:D001986]
Eosinophilia[MeSHID:D004802]
Asthma[MeSHID:D001249]
Status Asthmaticus[MeSHID:D013224]
Dermatitis
Atopic[MeSHID:D003876]
Nasal Polyps[MeSHID:D009298]
eosinophil[MeSHID:D004804]
Phenotype[MeSHID:D010641]
Prescription procedure[MeSHID:D055656]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 50.92 approved unknown
click here to return to the previous page